Pharmacyclics (PCYC) Inactive 10-Q2012 Q2 Quarterly report

Filed: 9 Feb 12, 12:00am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. freshman Avg

New words: abexinostat, accrued, analyze, arbitration, assist, assistance, attention, BESP, Biotech, bone, case, causality, charged, collectability, commensurate, committee, comply, component, Confidential, costly, cough, deliverable, devote, differentiation, difficulty, disagree, discount, Discrete, divided, earned, effort, element, equivalent, evenly, exited, external, fatigue, federal, Fifty, foreign, fully, global, globally, GmbH, Group, harmed, hinder, implementation, incremental, inventory, IRC, irreversible, Janssen, Johnson, judgment, labor, leasehold, lengthen, likelihood, litigation, made, mild, mix, MM, moderate, myeloma, nature, negative, negatively, notice, persuasive, pivotal, preliminary, prescribed, properly, proportional, realized, reclassified, recommended, recover, recruiting, reelection, reevaluated, reevaluation, rendered, requested, respiratory, Secretary, shorten, skilled, stand, standalone, state, statutory, stop, strategy, sublicense, successful, Switzerland, symptomatic, Territory, tied, transact, travel, underlying, unrelated, unsuccessful, unusual, upper, verifiable, verified, Workshop

Removed: computation, deficit, ending, entirety, invested, issuable, lymph, million, nodal, node, offering, PCI, planned, seek, uncommon

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Related press release

PCYC similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32.1

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350

In connection with the Quarterly Report of Pharmacyclics, Inc., a Delaware corporation (the “Company”), on Form 10-Q for the quarter ended December 31, 2011 as filed with the Securities and Exchange Commission (the “Report”), I, Robert W. Duggan, Chairman of the Board and Chief Executive Officer

of the Company, certify, pursuant to § 906 of the Sarbanes-Oxley Act of 2002 (18 U.S.C. § 1350), that to my knowledge:

(1) The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

/s/ ROBERT W. DUGGAN
Robert W. Duggan Chairman of the Board and Chief Executive Officer February 9, 2012

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350

In connection with the Quarterly Report of Pharmacyclics, Inc, a Delaware corporation (the “Company”), on Form 10-Q for the quarter ended December 31, 2011 as filed with the Securities and Exchange Commission (the “Report”), I, Rainer M. Erdtmann, Vice President, Finance and Administration and Secretary of the Company, certify, pursuant to § 906 of the Sarbanes-Oxley Act of 2002 (18 U.S.C. § 1350), that to my knowledge:

(1) The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

/s/ RAINER M. ERDTMANN
Rainer M. Erdtmann Vice President, Finance and Administration and Secretary (Principal Accounting and Financial Officer) February 9, 2012

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.